PharVision Advisers’s Pediatrix Medical MD Stock Holding History

PharVision Advisers’s Portfolio MD Stock Details MD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,644	Closed	-$245K	–	418
2024 Q4	$245K	Buy	+18,644	New	+$257K	0.21%	232

Other funds holding MD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PharVision Advisers's MD Position: Q1 2025 in Review

PharVision Advisers sold out of Pediatrix Medical (MD) in Q1 2025, closing a stake of 18,644 shares — an estimated $245K sold.

PharVision Advisers first reported a position in MD in Q4 2024 and held it in 1 quarter. The position peaked at $245K in Q4 2024. 241 funds tracked by Wall St. Rank hold MD as of Q1 2025.

PharVision Advisers reported no remaining Pediatrix Medical position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 18,644 Pediatrix Medical shares in Q1 2025, an estimated $245K.
PharVision Advisers first reported a position in Pediatrix Medical in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Pediatrix Medical position peaked at $245K in Q4 2024.
241 funds tracked by Wall St. Rank held Pediatrix Medical as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.